Prolia (Denosumab) and Rosuvastatin Interaction

Why This Combination Is Frequently Prescribed

Postmenopausal women and older adults often carry dual diagnoses of osteoporosis and cardiovascular risk. That overlap makes denosumab plus a statin one of the most common multi-drug pairings in this population.

The FREEDOM trial (N=7,868) enrolled postmenopausal women aged 60 to 90 with osteoporosis. Baseline lipid-lowering therapy use, including statins, was permitted and documented. No signal of excess adverse events emerged in participants who took both a statin and denosumab compared with those on denosumab alone [1]. A separate post-hoc analysis of FREEDOM extension data covering 10 years of denosumab exposure confirmed no new safety signals in patients on concurrent medications, including HMG-CoA reductase inhibitors [2].

Rosuvastatin itself was studied in the JUPITER trial (N=17,802), which included women over 60 with elevated hsCRP [3]. Concomitant bisphosphonate and anti-resorptive use was not an exclusion criterion, and no interaction signal was flagged.

The clinical reality is straightforward: these patients need both drugs, and the pharmacology supports using them together.

Pharmacokinetic Independence: Why No Interaction Exists

Denosumab and rosuvastatin are cleared by completely unrelated biological systems. Understanding why they do not interact requires a brief look at each drug's disposition.

Denosumab is a fully human IgG2 monoclonal antibody targeting RANK ligand. Like all therapeutic antibodies, it is degraded by intracellular proteolysis within the reticuloendothelial system. It does not undergo hepatic phase I or phase II metabolism. It is not a substrate, inhibitor, or inducer of any cytochrome P450 isoenzyme, and it does not interact with P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or any other known drug transporter [4]. The Prolia FDA prescribing information states: "No formal drug interaction studies have been conducted with Prolia," specifically because the antibody's clearance pathway makes metabolic drug interactions biologically implausible [4].

Rosuvastatin enters hepatocytes primarily via OATP1B1 and OATP1B3 transporters. It undergoes limited metabolism by CYP2C9 (approximately 10% of total clearance). About 90% of the absorbed dose is excreted unchanged in bile and feces [5]. Known interactions with rosuvastatin involve drugs that inhibit OATP1B1/1B3 (cyclosporine, certain protease inhibitors) or that alter its renal clearance. The Crestor FDA label lists specific interacting agents. Monoclonal antibodies, including denosumab, are not among them [5].

No CYP overlap. No transporter overlap. No protein-binding displacement. The pharmacokinetic verdict is clear.

Pharmacodynamic Considerations and Overlapping Side Effects

While the two drugs lack a pharmacokinetic interaction, clinicians should be aware of overlapping adverse-effect profiles that could complicate symptom attribution.

Musculoskeletal pain is reported with both agents. In FREEDOM, back pain occurred in 34.7% of denosumab-treated patients versus 34.6% on placebo, and arthralgia in 11.7% versus 11.3% [1]. Statin-associated muscle symptoms (SAMS) affect an estimated 7% to 29% of statin users depending on the definition used, though blinded trials consistently show lower rates of 1.5% to 5% [6]. When a patient on both drugs reports new-onset myalgia, the differential must include statin myopathy (check creatine kinase), denosumab-related musculoskeletal pain, and simple mechanical causes.

A practical triage approach: if CK is elevated above 5 times the upper limit of normal, suspect the statin. If CK is normal and pain is diffuse or axial, consider denosumab-related musculoskeletal effects or an unrelated cause. Symptom onset timing helps too. SAMS typically begins within weeks to months of statin initiation or dose increase. Denosumab-related pain can occur at any point during therapy.

Hypocalcemia is a denosumab-specific risk with no statin contribution. The Prolia label carries a warning for severe, symptomatic hypocalcemia, particularly in patients with renal impairment (CKD stage 4 or 5) [4]. Rosuvastatin does not affect calcium or vitamin D metabolism. If hypocalcemia develops in a patient on both drugs, the statin is not the cause.

Calcium, Vitamin D, and Statin Co-Administration

All patients receiving denosumab should take supplemental calcium (at least 1,000 mg daily) and vitamin D (at least 400 IU daily) unless hypercalcemia is present [4]. This requirement is unaffected by statin therapy.

One question patients raise: does calcium supplementation interfere with rosuvastatin absorption? The answer is no. Rosuvastatin absorption is not meaningfully affected by divalent cations. Unlike certain antibiotics (tetracyclines, fluoroquinolones), statins do not form chelation complexes with calcium. The Crestor prescribing information does not list calcium or vitamin D supplements among interacting substances [5].

Antacids containing aluminum and magnesium hydroxide can reduce rosuvastatin plasma concentrations by approximately 50% when given simultaneously [5]. The guidance is to dose rosuvastatin at least 2 hours before the antacid. Standard calcium carbonate or calcium citrate supplements at typical doses do not produce this effect.

Monitoring Recommendations for Dual Therapy

No additional monitoring is required beyond what each drug demands independently. Treat the monitoring schedule as additive, not synergistic.

For denosumab, the Endocrine Society 2020 guidelines and the Prolia label recommend checking serum calcium before each dose (administered every 6 months). Patients with CKD stage 4 to 5 require more frequent calcium monitoring, ideally within 2 weeks of each injection [4]. Dental exams should be performed before initiation and periodically thereafter to screen for osteonecrosis of the jaw, reported in 0.05% to 0.1% of osteoporosis-dose patients [7].

For rosuvastatin, the 2018 ACC/AHA cholesterol guideline recommends a fasting lipid panel 4 to 12 weeks after initiation or dose adjustment, then every 3 to 12 months. Hepatic transaminases should be checked at baseline. CK measurement is not required routinely but should be obtained if the patient reports muscle symptoms [8].

"There is no pharmacologic rationale for altering monitoring frequency when denosumab and a statin are co-prescribed," according to the American Association of Clinical Endocrinology 2020 osteoporosis guideline [9].

Dose Adjustment: None Required

Neither drug requires dose modification when given with the other.

Denosumab is administered as a fixed 60 mg subcutaneous injection every 6 months for osteoporosis. There is no dose titration, and concomitant medications do not change this regimen [4].

Rosuvastatin dosing ranges from 5 mg to 40 mg daily. The starting dose depends on LDL-C target, patient risk, and specific populations (5 mg for Asian patients, patients on certain interacting drugs like cyclosporine). Denosumab has no bearing on rosuvastatin dose selection [5].

The drugs can be taken on the same day. No spacing requirement exists because there is no absorption, distribution, metabolism, or excretion interaction between them.

Bone-Protective Effects of Statins: An Emerging but Unproven Hypothesis

Some preclinical and observational data suggest statins may have independent bone-protective effects through stimulation of BMP-2 and osteoblast differentiation. A 2017 meta-analysis of 33 observational studies found that statin use was associated with a 17% reduction in any fracture risk (pooled OR 0.83, 95% CI 0.76 to 0.91) [10]. A subset analysis of rosuvastatin-specific data was limited by small sample sizes.

These findings are hypothesis-generating only. No randomized controlled trial has confirmed a fracture-reduction benefit from any statin. The JUPITER trial was not designed or powered to detect fracture outcomes [3]. Clinicians should not prescribe rosuvastatin for bone health, and patients should not expect additive skeletal benefit from combining a statin with denosumab.

"Observational fracture data for statins remain confounded by the healthy-user effect, and no guideline recommends statins for osteoporosis prevention," per the NOF Clinician's Guide to Prevention and Treatment of Osteoporosis [11].

Special Populations

Chronic kidney disease. Denosumab does not require renal dose adjustment, but CKD stage 4 to 5 patients face higher hypocalcemia risk [4]. Rosuvastatin is contraindicated at the 40 mg dose in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), and the starting dose should be 5 mg in this group [5]. These adjustments are independent of each other.

Older adults (age 75+). Both drugs are commonly used in this group. No age-specific interaction concern exists. Fall risk assessment should be part of routine care, as both osteoporosis and statin-related muscle weakness (though debated) could contribute.

Patients on other interacting drugs. If the patient takes a drug that genuinely interacts with rosuvastatin (e.g., gemfibrozil, cyclosporine, certain antivirals), the statin dose may need reduction per its label. Denosumab does not compound these interactions.

When to Contact the Prescriber

Patients should reach out to their physician if they develop any of the following while on both medications: muscle pain, tenderness, or weakness (especially with fever or malaise); numbness or tingling around the mouth, fingers, or toes (possible hypocalcemia); dark-colored urine (possible rhabdomyolysis, rare); or jaw pain or dental problems (screen for ONJ).

These symptoms relate to individual drug risks, not to an interaction between them. The distinction matters for accurate triage.

The Bottom Line on Co-Prescribing

Denosumab 60 mg SC every 6 months and rosuvastatin 5 to 40 mg daily can be prescribed together without dose modification, timing restrictions, or additional monitoring. The FDA labels, major DDI databases (Lexicomp, Micromedex, Clinical Pharmacology), and published trial data all support this conclusion. Monitor each drug per its own guideline: calcium and vitamin D status for denosumab, lipid panel and liver enzymes for rosuvastatin, and CK only if muscle symptoms develop.